Chip stocks fall with Nvidia after data center rev disappointment
SOUTHAMPTON, UK - Synairgen PLC (LON:SYNG) announced the appointment of John Bradshaw as an independent Non-Executive Director and Chair of the Audit Committee, effective today. Bradshaw brings over 30 years of experience in financial roles across various UK companies, including positions as Chair of Audit Committee for two AIM listed companies and CFO of Syncona Investment Management Limited.
Mark Parry-Billings, Chairman of Synairgen, expressed confidence in Bradshaw’s expertise, particularly in the biotech sector, as the company gears up for the Phase 2 INVENT trial targeting viral pneumonia in mechanically-ventilated patients. Bradshaw’s appointment follows the company’s recent General Meeting on March 28, 2025.
Bradshaw stated his enthusiasm for joining Synairgen at a critical juncture, highlighting the potential impact of their investigational treatment for a patient demographic with significant medical needs. This news is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.